Disappointment Surrounding Alzheimer’s Treatment Has Reached Almost Mythical Heights. But Is There A ‘Cabal’ Behind All Those Failures?

For some experts it is increasingly apparent that there is another, more disturbing reason for the tragic lack of progress being made in Alzheimer's research. A group of researchers had been so determined that one approach would work, few tried anything else. In other pharmaceutical news: AbbVie announces $63 billion deal to acquire Allergan, an analysis finds drugmakers often commit to follow-up studies after approval but few of them are new; and more.

from Kaiser Health News http://bit.ly/31VkRJS